生物制剂疗法在重度哮喘治疗中的研究进展  

Research progress of biological therapy in the treatment of severe asthma

作　　者：田春燕[1] 王星壹 李竹英[1] Tian Chunyan;Wang Xingyi;Li Zhuying(Respiratory Department,the First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150006,China)

机构地区：[1]黑龙江中医药大学附属第一医院呼吸科,黑龙江哈尔滨150006

出　　处：《中国急救医学》2024年第12期1099-1104,共6页Chinese Journal of Critical Care Medicine

基　　金：国家自然科学基金青年项目(82104761);国家自然科学基金面上项目(82074365,82274420)。

摘　　要：重度哮喘是需要第4级或第5级哮喘药物治疗才能够维持控制或即使在上述治疗下仍表现为“未控制”的哮喘。目前生物制剂疗法为重度哮喘患者提供了新的治疗方法。本文将对治疗重度哮喘的生物制剂进行综述,阐述现有生物制剂的作用机制、疗效和安全性等,并在此基础上对生物制剂疗法的发展方向进行展望。Severe asthma is the type of asthma which can be controlled with the treatment of grade 4 or grade 5 asthma medication or appears"uncontrolled"even with the above treatment.At present,biological therapy provides a new treatment method for the patients with severe asthma.This paper will review the biological agents for the treatment of severe asthma and explain the mechanism of action,efficacy and safety of existing biologics.On this basis,the development direction of biological therapy was prospected.

关 键 词：重度哮喘 生物制剂 单克隆抗体 分型 机制 疗效 安全性 

分 类 号：R562.25[医药卫生—呼吸系统]